Placental dermatan sulfate: Isolation, anticoagulant activity, and association with heparin cofactor II

Blood

Volumn 107, Issue 7, 2006, Pages 2753-2758

  Giri, Tusar K ^a   Tollefsen, Douglas M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; HEPARIN COFACTOR II;

ANION EXCHANGE CHROMATOGRAPHY; ANTICOAGULATION; ARTICLE; BLOOD VESSEL; DRUG ISOLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PLACENTA; PLACENTA VILLUS; PRIORITY JOURNAL; SYNCYTIOTROPHOBLAST;

EID: 33645513210     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3755     Document Type: Article

References (43)

1. Arias F, Rodriquez L, Rayne SC, Kraus FT. Maternal placental vasculopathy and infection: two distinct subgroups among patients with preterm labor and preterm ruptured membranes. Am J Obstet Gynecol. 1993;168:585-591.
2. Arias F, Victoria A, Cho K, Kraus F. Placental histology and clinical characteristics of patients with preterm premature rupture of membranes. Obstet Gynecol. 1997;89:265-271.
3. Arias F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med. 1998;7:277-286.
4. Kraus FT, Acheen VI. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol. 1999;30:759-769.
5. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta. 2002;23:337-342.
6. Sun CC, Revell VO, Belli AJ, Viscardi RM. Discrepancy in pathologic diagnosis of placental lesions. Arch Pathol Lab Med. 2002;126:706-709.
7. Villarreal C, Garcia-Aguirre G, Hernandez C, Vega O, Borbolla JR, Collados MT. Congenital thrombophilia associated to obstetric complications. J Thromb Thrombolysis. 2002;14:163-169.
8. Nelson DM, Crouch EC, Curran EM, Farmer DR. Trophoblast interaction with fibrin matrix: epithelialization of perivillous fibrin deposits as a mechanism for villous repair in the human placenta. Am J Pathol. 1990;136:855-865.
9. Gersell DJ. Selected vascular lesions of the placenta. Clin Lab Med. 1995;15:611-629.
10. Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy J, Gruel Y. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood. 1996;88:900-906.
11. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 1983;258:6713-6716.
12. Vossen CY, Preston FE, Conard J, et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost. 2004;2:592-596.
13. Aihara K, Azuma H, Takamori N, et al. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation. 2004;109:2761-2765.
14. Schillinger M, Exner M, Sabeti S, et al. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Thromb Haemost. 2004;92:1108-1113.
15. Takamori N, Azuma H, Kato M, et al. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation. 2004;109:481-486.
16. Bellart J, Gilabert R, Cabero L, Fontcuberta J, Monasterio J, Miralles RM. Heparin cofactor II: a new marker for pre-eclampsia. Blood Coagul Fibrinolysis. 1998;9:205-208.
17. Bellart J, Gilabert R, Fontcuberta J, Carreras E, Miralles RM, Cabero L. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation. Am J Perinatol. 1998;15:81-85.
18. Massouh M, Jatoi A, Gordon EM, Ratnoff OD. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med. 1989;114:697-699.
19. Liu L, Dewar L, Song Y, et al. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost. 1995;73:405-412.
20. Andrew M, Mitchell L, Berry L, et al. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest. 1992;89:321-326.
21. Achur RN, Valiyaveettil M, Alkhalil A, Ockenhouse CF, Gowda DC. Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected erythrocytes to the placenta. J Biol Chem. 2000;275:40344-40356.
22. Delorme MA, Xu L, Berry L, Mitchell L, Andrew M. Anticoagulant dermatan sulfate proteoglycan (decorin) in the term human placenta. Thromb Res. 1998;90:147-153.
23. Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem. 1962;4:330-334.
24. Teien AN, Abildgaard U, Höök M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res. 1976;8:859-867.
25. Dietrich CP, Dietrich SM. Electrophoretic behaviour of acidic mucopolysaccharides in diamine buffers. Anal Biochem. 1976;70:645-647.
26. Cavalcante MC, Allodi S, Valente AP, et al. Occurrence of heparin in the invertebrate styela plicata (Tunicata) is restricted to cell layers facing the outside environment: an ancient role in defense? J Biol Chem. 2000;275:36189-36186.
27. Lian F, He L, Colwell NS, Lollar P, Tollefsen DM. Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin. Biochemistry. 2001;40:8508-8513.
28. Couchman JR, Caterson B, Christner JE, Baker JR. Mapping by monoclonal antibody detection of glycosaminoglycans in connective tissues. Nature. 1984;307:650-652.
29. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol. 1992;119:961-975.
30. Trowbridge JM, Gallo RL. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology. 2002;12:117R-125R.
31. Maimone MM, Tollefsen DM. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem. 1990;265:18263-18271.
32. Pavão MS, Aiello KR, Werneck CC, et al. Highly sulfated dermatan sulfates from Ascidians: structure versus anticoagulant activity of these glycosaminoglycans. J Biol Chem. 1998;273:27848-27857.
33. Mascellani G, Liverani L, Bianchini P, et al. Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally over-sulphated sequences of dermatan sulphate. Biochem J. 1993;296:639-648.
34. Mascellani G, Liverani L, Prete A, Guppola PA, Bergonzini G, Bianchini P. Relative influence of different disulphate disaccharide clusters on the HCII-mediated inhibition of thrombin by dermatan sulphates of different origins. Thromb Res. 1994;74:605-615.
35. Tollefsen DM, Peacock ME, Monafo WJ. Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II. J Biol Chem. 1986;261:8854-8858.
36. Lysiak JJ, Hunt J, Pringle GA, Lala PK. Localization of transforming growth factor beta and its natural inhibitor decorin in the human placenta and decidua throughout gestation. Placenta. 1995;16:221-231.
37. de Luca Brunori I, Battini L, Brunori E, et al. Placental barrier breakage in preeclampsia: ultrastructural evidence. Eur J Obstet Gynecol Reprod Biol. 2005;118:182-189.
38. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol. 2003;189:1173-1177.
39. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109:213-219.
40. Oike Y, Kimata K, Shinomura T, Suzuki S, Takahashi N, Tanabe K. A mapping technique for probing the structure of proteoglycan core molecules. J Biol Chem. 1982;257:9751-9758.
41. Hiyama K, Okada S. Crystallization and some properties of chondroitinase from Arthrobacter aurescens. J Biol Chem. 1975;250:1824-1828.
42. Michelacci YM, Dietrich CP. A comparative study between a chondroitinase B and a chondroitinase AC from Flavobacterium heparinum: isolation of a chondroitinase AC-susceptible dodecasaccharide from chondroitin sulphate B. Biochem J. 1975;151:121-129.
43. Linker A, Hovingh P. Isolation and characterization of oligosaccharides obtained from heparin by the action of heparinase. Biochemistry. 1972;11:563-568.